

(R, S'),(R, R')-AMPHETAMINIL, COMPOSITIONS AND USES THEREOF**CROSS-REFERENCE TO RELATED APPLICATION**

Priority is claimed under 35 U.S.C. § 119(e) to Provisional Application Serial No. 60/297,386, filed June 11, 2001, which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Amphetaminil, or alpha-[(1-methyl-2-phenylethyl)amino]benzeneacetonitrile, also known under the trademarks AN1 and APONEURON, is a neuropharmacologically-active compound that has been marketed for the treatment of narcolepsy, for use as a tonic, and for hypotension in combination with other components. One study has indicated potential utility in attention-deficit hyperactivity disorder (ADHD).

The amphetaminil molecule possesses two dissymmetric centers resulting in four possible enantiomers: (R,R')-amphetaminil; (S,S')-amphetaminil; (R,S')- amphetaminil; and (S, R')-amphetaminil. The commercially-available form (AN1) is a racemate, having a ratio of the (R,R'),(S,S') diastereomers to the (R,S'),(S,R') diastereomers of about 4-5:1 (Salvesen et al., 1974, *Arzneim-Forschung* (Drug Research) 24:137-140). However, amphetaminil that is substantially enantiomerically pure at the first dissymmetric center (pure R: (R,S'),(R,R')-amphetaminil, also referred to as alpha-[(1R-Methyl-2-phenylethyl)amino]benzeneacetonitrile; pure S: (S,R'),(S,S')-amphetaminil, also referred to as alpha-[(1S-Methyl-2-phenylethyl)amino]benzeneacetonitrile) has not been prepared or evaluated for pharmacological activity.

It is towards identifying pharmacological activity in optical isomers of amphetaminil and improved utility of such isomers that the present invention is directed.

1
2 The citation of any reference herein should not be construed as an admission that such
3 reference is available as "Prior Art" to the instant application.
4

5 SUMMARY OF THE INVENTION

6 In one broad aspect, the invention is directed to a pharmaceutical composition containing
7 at least an effective amount of (R,R'),(R,S')-amphetaminil sulfate or another
8 pharmaceutically-acceptable salt thereof, substantially free of (S,R'),(S,S')-
9 amphetaminil, and at least one pharmaceutically-acceptable carrier, diluent, excipient or
10 additive. The pharmaceutical composition may contain other active agents. It may also
11 be provided in a controlled release formulation or an immediate release formulation. The
12 enantiomeric purity is preferably at least 90%, more preferably at least 95%, and most
13 preferably at least 99%. In one embodiment, an oral dosage form contains about 0.1 to
14 about 100 mg of (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-
15 acceptable salt thereof; preferably, it contains about 1 to about 50 mg of (R,R'),(R,S')-
16 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof.
17

18 In another aspect, the invention is directed to a method for the prophylaxis or treatment of
19 a human condition or disease requiring or benefitting from a central stimulant by at least
20 administering an effective amount of a pharmaceutical composition containing at least
21 (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-acceptable salt thereof,
22 substantially free of (S,R'),(S,S')-amphetaminil. Administering may be, by way of non-
23 limiting example, parenteral, transmucosal or transdermal. Non-limiting examples of

1 transmucosal administration include orally, nasally, or rectally. Preferably,
2 administration is oral. Non-limiting examples of parenteral administration include intra-
3 arterial, intravenous, intramuscular, intradermal, subcutaneous, intraperitoneal,
4 intraventricular, or intracranial. The amount administered may be about 0.1 to about 100
5 mg daily, preferably about 1 to about 50 mg daily. It may be administered in from one to
6 about four unit doses per day, preferably in one or two unit doses per day.

7
8 The amount of (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-
9 acceptable salt thereof in the pharmaceutical compositions or dosage forms of the
10 invention is greater than about 90% of the weight of the total amphetaminil; preferably
11 greater than about 95% of the weight of the total amphetaminil; and most preferably
12 greater than about 99% of the weight of the total amphetaminil.

13
14 The amount of (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-
15 acceptable salt thereof, substantially free of (S,R'),(S,S')-amphetaminil, in a
16 pharmaceutical composition or dosage form may be administered together with a
17 pharmaceutically-acceptable carrier, diluent, excipient or additive. Other active agents
18 may also be present.

19
20 By way of non-limiting examples, the conditions and diseases prophylaxed or treated
21 with a pharmaceutical composition of dosage form of the invention includes narcolepsy,
22 attention-deficit hyperactivity disorder (ADHD), depression, Parkinson's disease,
23 cognitive dysfunction, Alzheimer's disease, renal dysfunction, hypotension, asthma,

1 obesity, nicotine withdrawal, apathy, potentiating the activity of a conventional
2 antidepressant, potentiating opiate activity for the treatment of pain, and decreased
3 energy associated with chemotherapy or radiation treatment. It may be used for any
4 condition or disease in which racemic amphetaminil, amphetamine, and more
5 specifically, D-amphetamine, have been used. Moreover, less activation or promotion of
6 stereotypic behavior is elicited by this composition than by racemic amphetaminil, and
7 therefore may be less likely to exhibit or exacerbate movement disorders in patients in
8 which this compound is administered. This is particularly beneficial to the treatment of
9 Parkinson's disease and individuals with ADHD who exhibit tics.

10
11 It is a further object of the invention to provide for a method for the prophylaxis or
12 treatment of a human condition or disease desirably benefiting from preferential
13 activation of mesolimbic-mediated behaviour by at least administering to the human an
14 effective amount of a pharmaceutical composition comprising (R,R'),(R,S')-
15 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof, substantially
16 free of (S,R'),(S,S')-amphetaminil. Administering may be, by way of non-limiting
17 example, parenteral, transmucosal or transdermal. Non-limiting examples of
18 transmucosal administration include orally, nasally, or rectally. Preferably,
19 administration is oral. Non-limiting examples of parenteral administration include intra-
20 arterial, intravenous, intramuscular, intradermal, subcutaneous, intraperitoneal,
21 intraventricular, or intracranial. The amount administered is about 0.1 to about 100 mg
22 daily, preferably about 1 to about 50 mg daily. It may be administered in from one to
23 about four unit doses per day, preferably in one or two unit doses per day.

1

2 The amount of (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-
3 acceptable salt thereof in the pharmaceutical compositions or dosage forms of this aspect
4 of the invention is greater than about 90% of the weight of the total amphetaminil;
5 preferably greater than about 95% of the weight of the total amphetaminil; and most
6 preferably greater than about 99% of the weight of the total amphetaminil.

7

8 The amount of (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-
9 acceptable salt thereof, substantially free of (S,R'),(S,S')-amphetaminil, in a
10 pharmaceutical composition or dosage form may be administered together with a
11 pharmaceutically-acceptable carrier, diluent, excipient or additive. Other active agents
12 may also be present.

13

14 These and other aspects of the present invention will be better appreciated by reference to
15 the following drawings and Detailed Description.

16

17 BRIEF DESCRIPTION OF THE DRAWINGS

18

19 Figures 1 A, B and C depict the locomotor activity, cumulative locomotor activity and
20 dose response curve, respectively, from an *in-vivo* study with amphetamine.

21

22 Figures 2 A, B and C depict the locomotor activity, cumulative locomotor activity and
23 dose response curve, respectively, from an *in-vivo* study with fusaric acid.

1
2 Figures 3 A, B and C depict the locomotor activity, cumulative locomotor activity and
3 dose response curve, respectively, from an *in-vivo* study with (R, R'),(R, S')-
4 amphetaminil.
5
6 Figures 4 A, B and C depict the locomotor activity, cumulative locomotor activity and
7 dose response curve, respectively, from an *in-vivo* study with (R, S'), (R, R'),(S, R'),(S,
8 S')-amphetaminil.
9
10 Figures 5 A, B and C depict the stereotypy scores, total stereotypy score and dose
11 response curve, respectively, from an *in-vivo* study with amphetamine
12
13 Figures 6 A, B and C depict the stereotypy scores, total stereotypy score and dose
14 response curve, respectively, from an *in-vivo* study with fusaric acid.
15
16 Figures 7 A, B and C depict the stereotypy scores, total stereotypy score and dose
17 response curve, respectively, from an *in-vivo* study with (R, R'),(R, S')-amphetaminil.
18
19 Figures 8 A, B and C depict the stereotypy scores, total stereotypy score and dose
20 response curve, respectively, from an *in-vivo* study with (R, S'),(R, R'),(S, R'),(S, S')-
21 amphetaminil.
22

1 DETAILED DESCRIPTION OF THE INVENTION

2 The present invention is directed to pharmaceutical compositions and methods of use of a
3 form of amphetaminil substantially pure at the first dissymmetric center with heretofore
4 unrecognized and unexpected properties. As identified by the inventors herein, the
5 (R,S'),(R,R') form of amphetaminil ((R,S'),(R,R')-amphetaminil, also referred to as alpha-
6 [(1R-Methyl-2-phenylethyl)amino]benzeneacetonitrile]) possesses certain improved
7 pharmacological and dose-responsive activities over that of racemic amphetaminil, and
8 thus is useful in a pharmaceutical composition substantially free of (S,R'),(S,S')-
9 amphetaminil for the treatment of a number of conditions and diseases for which racemic
10 amphetaminil, as well as other related compounds including amphetamine, and in
11 particular D-amphetamine, have been used therapeutically. Moreover, reduced dosage
12 and attendant reduced side effects or adverse effects or events are benefits of treating
13 individuals with only an active form of amphetaminil for such indications, reducing
14 manufacturing costs, size and packaging of dosage forms, and providing a smaller oral
15 dosage form for better patient compliance.

16
17 The uses provided herein for a pharmaceutical composition comprising (R,S'),(R,R')-
18 amphetaminil embraces all of the uses heretofore identified for the racemate as well as
19 that of other compounds in the same therapeutic category. As such, amphetaminil may
20 be used for conditions for which treatment is indicated for a central nervous system
21 stimulant. Such specific uses include but are not limited to narcolepsy, attention-deficit
22 hyperactivity disorder (ADHD), depression, Parkinson's disease, cognitive dysfunction,
23 Alzheimer's disease, renal dysfunction, hypotension, asthma, obesity, nicotine

1 withdrawal, apathy, and decreased energy associated with chemotherapy or radiation
2 treatment, optionally in combination with other agents. Such combinations include use
3 with conventional antidepressants and opiates, for the treatment of depression and pain
4 control, respectively. These uses are merely examples are not intended to be in any way
5 limiting. For example, Martindale's reports that amphetaminil is prescribed as a central
6 stimulant given by mouth in doses of 10 to 30 mg daily in the treatment of narcolepsy or
7 narcoleptic syndrome. It is available from Krugmann GmbH (Limburg, Germany) under
8 the name AN1, and in two formulations from Voigt GmbH (Limburg, Germany): Ton-
9 O₂, containing heptaminol HCl, amphetaminil and adenosine indicated for treatment of
10 hypotension, and Vit-O₂, containing amphetaminil and inositol nicotinate, indicated for
11 use as a tonic.

12
13 The (R,R'),(R,S') form of amphetaminil, based on the studies described herein, is
14 particularly suited for the treatment of conditions and diseases in which preferential
15 activity in the mesolimbic area of the brain is desirable, such as in the treatment of
16 Parkinson's disease and in the ADHD patients who exhibit tics. As studies have shown
17 efficacy in the treatment of ADHD in children using racemic amphetaminil (Pacit et al.,
18 1996, Effect of Aponeuron in the treatment of children with hyperkinetic syndrome,
19 Ceska Slov Psychiatr 92:41-57), the use of this form of amphetaminil may be desirable.

20
21 U.S. Patents 6,166,032; 5,900,418; and 5,916,902 describe amphetaminil among other
22 central nervous system stimulant for treatment of nicotine withdrawal, obesity, and for

1 reducing the effects of antineoplastic disease treatment, respectively. All of the foregoing
2 utilities are embraced herein.

3

4 The invention is directed, in one aspect, to a substantially pure pharmaceutical
5 composition comprising (R,R'),(R,S')-amphetamine. Thus, the pharmaceutical
6 composition of the invention comprises (R,R'),(R,S')-amphetamine substantially free of
7 (S,R'),(S,S')-amphetamine. The terms "substantially free of (S,R'),(S,S')-
8 amphetamine" as used herein means that the composition contain at least about 90% by
9 weight of (R,R'),(R,S')-amphetamine and about 10% by weight or less of (S,R'),(S,S')-
10 amphetamine. In a preferred embodiment the terms "substantially free of the
11 (S,R'),(S,S')-amphetamine" mean that the composition contains at least 95% by weight
12 of (R,R'),(R,S')-amphetamine and 5% or less of (S,R'),(S,S')-amphetamine. In a most
13 preferred embodiment the terms "substantially free of (S,R'),(S,S')-amphetamine" means
14 that the composition contains at least 99% by weight of (R,R'),(R,S')-amphetamine and
15 1% or less of (S,R'),(S,S')-amphetamine.

16
17 As mentioned above, amphetamine possesses two dissymmetric centers, one of which is
18 part of the amphetamine-like portion of the molecule (and is the first to be set forth in the
19 chemical structure), and the second part of the benzeneacetonitrile-like portion of the
20 molecule (and is the second to be set forth, with a prime designation, in the chemical
21 structure). The compound hereindescribed is the R form at the first or amphetamine-like
22 dissymmetric center, and is racemic at the second, or benzeneacetonitrile-like center. Thus,
23 the amphetamine compound of the invention may be described as (R,R'),(R,S')-

1 amphetaminil or synonymously as alpha-[(1R-methyl-2-phenylethyl)amino]-
2 benzeneacetonitrile. Although the second dissymmetric center may be racemic, it may be
3 enriched in one form, or pure R' or S', without deviating from the teachings herein.
4 Thus, the invention may also be extended to a pure amphetaminil enantiomer of (R,R')-
5 amphetaminil or (R, S')-amphetaminil.

6
7 The Examples below provide a method for synthesis of (R,R'),(R,S')-amphetaminil from
8 chiral intermediates and stabilizing them as sulfate salts; however, any suitable method
9 may be used to either synthesize the desired compound from starting materials, or to
10 purify (R,R'),(R,S')-amphetaminil [or the individual (R,R') and (R,S') enantiomers] from
11 a racemic or other mixtures of amphetaminil of various ratios of stereoisomers. The
12 invention is not so limiting as to the method of preparation, but embraces (R,R'),(R,S')-
13 amphetaminil effectively in the absence of (S,S'),(S,R'), to the extent possible based on
14 cost, manufacturing, stability and other considerations. It will be apparent that several
15 advantages are offered both to the patient and the manufacturer of the agent when
16 (R,R'),(R,S')-amphetaminil is used effectively in the absence of (S,S'),(S,R'),
17 particularly for the conditions and diseases described herein, but it is not so limiting.

18
19 Moreover, while the sulfate salt of amphetaminil of the pharmaceutical composition of
20 the invention is preferred, and without other reference amphetaminil referred to
21 hereinthroughout is the sulfate salt (amphetaminil $\cdot \frac{1}{2} \text{H}_2\text{SO}_4$), any pharmaceutically
22 acceptable salt may be used. As will also be seen in the examples below, the sulfate salt
23 was found to stabilize the R enantiomers during the synthesis procedure. The invention

1 is also directed to a facile means for stabilizing the enantiomers by converting the
2 products of the synthetic reaction at the stage of formation of amphetaminil into sulfate
3 salts.

4
5 The pharmaceutical composition of the composition comprising (R,R'),(R,S')-
6 amphetaminil substantially free of (S,R'),(S,S')-amphetaminil may be formulated in any
7 pharmaceutically-acceptable carrier or excipient suitable for the route of administration
8 and dosing frequency desired. Preferably, an oral formulation is provided, comprising
9 the (R,R'),(R,S')-amphetaminil in a tablet or capsule. However, formulations for other
10 routes of administration are fully embraced herein, and the appropriate means for
11 formulation will be determinable by the skilled artisan. Formulations for injection, for
12 example, are also embraced herein.

13
14 According to the invention, the pharmaceutical composition of the invention may be
15 introduced parenterally or transmucosally, e.g., orally, nasally, or rectally, or
16 transdermally. Preferably, administration is oral. Examples of parenteral administration
17 include intra-arterial, intravenous, intramuscular, intradermal, subcutaneous,
18 intraperitoneal, intraventricular, and intracranial administration.

19
20 In yet another aspect of the present invention, provided are pharmaceutical compositions
21 of (R,R'),(R,S')-amphetaminil. Such pharmaceutical compositions may be for
22 administration for injection, or for oral, pulmonary, nasal or other forms of
23 administration. In general, comprehended by the invention are pharmaceutical

1 compositions comprising effective amounts of a low molecular weight component or
2 components, or derivative products, of the invention together with pharmaceutically
3 acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
4 Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate,
5 phosphate), pH and ionic strength; additives such as detergents and solubilizing agents
6 (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium
7 metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances
8 (e.g., lactose, mannitol); incorporation of the material into particulate preparations of
9 polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes.
10 Hylauronic acid may also be used. Such compositions may influence the physical state,
11 stability, rate of in vivo release, and rate of in vivo clearance of the present amphetaminil
12 composition. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack
13 Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by
14 reference. The compositions may be prepared in liquid form, or may be in dried powder,
15 such as lyophilized form.

16
17 In the case of oral delivery, contemplated for use herein are oral solid dosage forms,
18 which are described generally in Remington's Pharmaceutical Sciences, 18th Ed. 1990
19 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by
20 reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges,
21 cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate
22 the present compositions (as, for example, proteinoid microspheres reported in U.S.
23 Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be

1 derivatized with various polymers (e.g., U.S. Patent No. 5,013,556). A description of
2 possible solid dosage forms for the therapeutic is given by Marshall, K. In: Modern
3 Pharmaceutics Edited by G.S. Banker and C.T. Rhodes Chapter 10, 1979, herein
4 incorporated by reference. In general, the formulation will include the component or
5 components (or chemically modified forms thereof) and inert ingredients which allow for
6 protection against the stomach environment, and release of the biologically active
7 material in the intestine.

8
9 For the component (or derivative) the location of release may be the stomach, the small
10 intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in
11 the art has available formulations which will not dissolve in the stomach, yet will release
12 the material in the duodenum or elsewhere in the intestine. To ensure full gastric
13 resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more
14 common inert ingredients that are used as enteric coatings are cellulose acetate
15 trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50,
16 HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose
17 acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. These coatings may be
18 used as mixed films.

19
20 A coating or mixture of coatings can also be used on tablets, which are not intended for
21 protection against the stomach. This can include sugar coatings, or coatings which make
22 the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for
23 delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used.

1 The shell material of cachets could be thick starch or other edible paper. For pills,
2 lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

3

4 The therapeutic can be included in the formulation as fine multi-particulates in the form
5 of granules or pellets of particle size about 1 mm. The formulation of the material for
6 capsule administration could also be as a powder, lightly compressed plugs or even as
7 tablets. The therapeutic could be prepared by compression.

8

9 One may dilute or increase the volume of the therapeutic with an inert material. These
10 diluents could include carbohydrates, especially mannitol, alpha-lactose, anhydrous
11 lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be
12 also be used as fillers including calcium triphosphate, magnesium carbonate and sodium
13 chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500,
14 Emcompress and Avicell.

15

16 Disintegrants may be included in the formulation of the therapeutic into a solid dosage
17 form. Materials used as disintegrates include but are not limited to starch, including the
18 commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite,
19 sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel,
20 acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another
21 form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may
22 be used as disintegrants and as binders and these can include powdered gums such as

1 agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as
2 disintegrants.

3

4 Binders may be used to hold the therapeutic agent together to form a hard tablet and
5 include materials from natural products such as acacia, tragacanth, starch and gelatin.
6 Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose
7 (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could
8 both be used in alcoholic solutions to granulate the therapeutic.

9

10 An anti-frictional agent may be included in the formulation of the therapeutic to prevent
11 sticking during the formulation process. Lubricants may be used as a layer between the
12 therapeutic and the die wall, and these can include but are not limited to; stearic acid
13 including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid
14 paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium
15 lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular
16 weights, Carbowax 4000 or 6000.

17

18 Glidants that might improve the flow properties of the drug during formulation and to aid
19 rearrangement during compression might be added. The glidants may include starch,
20 talc, pyrogenic silica and hydrated silicoaluminate.

21

22 To aid dissolution of the therapeutic into the aqueous environment a surfactant might be
23 added as a wetting agent. Surfactants may include anionic detergents such as sodium

1 lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic
2 detergents might be used and could include benzalkonium chloride or benzethonium
3 chloride. The list of potential non-ionic detergents that could be included in the
4 formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene
5 hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and
6 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These
7 surfactants could be present in the formulation of the amphetaminil either alone or as a
8 mixture in different ratios.

9
10 Controlled release oral formulation may be desirable. The drug could be incorporated
11 into an inert matrix which permits release by either diffusion or leaching mechanisms,
12 e.g., gums. Slowly degenerating matrices may also be incorporated into the formulation.
13 Some enteric coatings also have a delayed release effect.

14
15 Another form of a controlled release of this therapeutic is by a method based on the Oros
16 therapeutic system (Alza Corp.), i.e. the drug is enclosed in a semipermeable membrane
17 which allows water to enter and push drug out through a single small opening due to
18 osmotic effects.

19
20 Other coatings may be used for the formulation. These include a variety of sugars which
21 could be applied in a coating pan. The therapeutic agent could also be given in a film
22 coated tablet and the materials used in this instance are divided into 2 groups. The first
23 are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl

1 cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-
2 methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene
3 glycols. The second group consists of the enteric materials that are commonly esters of
4 phthalic acid.

5
6 A mix of materials might be used to provide the optimum film coating. Film coating may
7 be carried out in a pan-coater or in a fluidized bed or by compression coating.

8
9 The foregoing provides mere examples of dosage forms of the present invention.
10 Moreover, (R,R'),(R,S')-amphetaminil may be formulated in combination with one or
11 more other pharmacologically active agents or compounds that are necessary or desirable
12 for achieving a desired pharmacological effect.

13
14 The dosage of (R,R'),(R,S')-amphetaminil will be readily determined for the particular
15 indication. For example, racemic amphetaminil is administered at 10 to 30 mg per day
16 for the treatment of narcolepsy. Based on the studies herein, and the identification of the
17 (R,R'),(R,S') compound as possessing the pharmacological activity of the racemate, a
18 dosage of 1 to about 50 mg per day is provided. However, as each condition to be treated
19 required a readily-determinable dose amount and frequency to achieve the desired effect,
20 this dosage is not so limiting, and doses from 0.1 mg up to about 100 mg are included
21 herein. As is noted in Figures 7 and 8 herein, the (R,R'),(R,S') form exhibits less
22 stereotypy than the racemic form of amphetaminil.

23

1 In a further, and theoretical analysis of the results obtained herein of which Applicants
2 have no duty to disclose and are not bound thereby, the effect on stereotypy activity of
3 the R form of amphetaminil indicates that it preferentially activates mesolimbic-mediated
4 behavior, and as such is useful for treatment of conditions and diseases mediated through
5 this part of the brain. Non-limiting examples of such conditions and diseases are set forth
6 herein, yet the invention embraces all such conditions and diseases in which a
7 preferentially mesolimbically-active compound is therapeutically useful.

8
9 The present invention may be better understood by reference to the following non-
10 limiting Examples, which are provided as exemplary of the invention. The following
11 examples are presented in order to more fully illustrate the preferred embodiments of the
12 invention. They should in no way be construed, however, as limiting the broad scope of
13 the invention.

14 15 **Example 1**

16 **Synthesis of Amphetaminil and Analytical Summary**

17
18 In preliminary studies, (+/-)-amphetaminil free base was synthesized. It was purified by
19 recrystallization to form a white crystalline solid. It was fully characterized; high field
20 proton NMR in deuteriochloroform showed a 5:1 ratio of diastereomers, but was clean
21 with respect to other impurities.

22

1 The (+) and (-) amphetaminils were then synthesized. These materials did not
2 recrystallize successfully from a variety of solvents tested. When any solid was isolated,
3 it rapidly liquefied at room temperature, consequently adequate purity could not be
4 obtained by this purification method. It was reasoned that the different behavior from the
5 racemate was due to the fact that enantiomerically pure materials can have different
6 crystallization properties from racemates, and will usually form lower melting solids.
7 Next, purification was attempted by formation of the HCl salt, followed by
8 recrystallization and free-up back to amphetaminil. This was unsuccessful, and showed
9 almost complete breakdown for all isomers.

10
11 Chromatographic purification of the (+) and (-) amphetaminil free bases was then
12 attempted, including silica gel, basic alumina, neutral alumina as well as deactivated
13 alumina and silica. Preparatory TLC was also attempted. All attempts led to very poor
14 recoveries and lower purities, indicating degradation, and no separation of diastereomers
15 was noted. Due to poor reverse phase HPLC results, reverse phase preparative
16 chromatography was not attempted. Normal Phase preparative purification using a chiral
17 HPLC Column also led to degradation.

18
19 A larger batch of (+)-amphetaminil was synthesized. Further experiments with
20 recrystallization of the free base were performed, but no improvements over the above
21 were found. In subsequent studies, various salts were used. The sulfate salts gave the
22 most promising results, with little breakdown.

23

1 The (+) and (-) amphetaminils were resynthesized to insure highest purity compounds
2 and converted to the sulfate salts immediately. Some further experimentation with the
3 sulfate salt showed it to be somewhat heat-sensitive, so rather than recrystallizing, the salt
4 was purified by trituration (washing) with solvent (ethanol/ether mix) to remove
5 impurities. It was found that the impurities formed during the synthesis could be
6 removed, but that a new impurity began to form as washing continued. Stopping at the
7 optimal point resulted in 3 products that were 98-99% pure by gas chromatography. The
8 (+/-) material, which was the most pure, was subjected to further analytical testing.

9
10 In order to insure a consistent ratio of the diastereomers, the racemic material was
11 resynthesized from racemic amphetamine sulfate previously obtained. It was
12 immediately made in to the sulfate salt without any recrystallization and purified by
13 trituration as with the (+) and (-) isomers.

14
15 A chiral analytical column proved to be more successful in separation of the isomers of
16 amphetaminil. Sample preparation involved freeing up the sulfate with an ammonium
17 hydroxide solution followed by extraction with hexane. The sample would then be
18 injected. Even with rapid injection, breakdown was evident by the formation of a large
19 benzaldehyde peak that would increase with time as the sample solution sat around.
20 However, consistent separations of all 4 isomers was obtained, with the following results:

21


	(R,R')- Amphetaminil	(S,S')- Amphetaminil	(R,S')- Amphetaminil	(S,R')- Amphetaminil
CSQ-1680A	50%	0%	50%	0%
CSQ-1680E	25%	25%	25%	25%

This was in contrast to the result obtained by NMR for the racemic recrystallized amphetaminil, which showed a 4-5:1 ratio in the original analysis of the free base. These results were confirmed by NMR analysis. Based on the information we learned about the stability of amphetaminil in various solvents, we obtained analyses of the sulfate in acetone-D6 as well as freed up sample in deuteriochloroform. Various degrees of degradation were seen in these NMRs, but the ratio in all three products closely matched the results obtained from chiral LC analysis. An accurate measurement of the ratio of isomers is difficult due to the instability of the material in solution and the analytical variability in NMR analysis, but an averaging of our results resulted in the ratios indicated in the table above.

Example 2


Synthesis procedure for (R, R'),(R,S')-Amphetaminil Sulfate; CSQ-1680A

Step-1 – (1S, 2R)-(+)-norephedrine hydrochloride



The HCl salt of (1S, 2R)-(+)-norephedrine was made by bubbling HCl gas into a flask containing (1S, 2R)-(+)-norephedrine (200 grams) in ethyl ether (500mL). The salt was filtered, washed with ethyl ether, and dried to yield 150g of (1S, 2R)-(+)-norephedrine hydrochloride.


Step2 – (1R, 2R) – norchloroephedrine hydrochloride



Compound	Formula Weight	Mass Used	Moles	Equivalents	Vendor and Lot#
Phosphorus pentachloride	208.24	43.7g	0.21	1.3	Aldrich 13713PS
(1S,2R)-(+)-Norephedrine hydrochloride	187.67	30.0g	0.16	1.0	Aldrich 01223JF

(1S, 2R)-(+)-norephedrine hydrochloride was added portionwise to a 500mL round bottom flask containing phosphorus pentachloride in chloroform (300mL) and was stirred at room temperature under nitrogen overnight. The norchloroephedrine salt that precipitated out of the reaction was filtered, washed with chloroform, and dried to yield 22.4 grams (68% yield).


Step 3 – (-)-amphetamine



Compound	Formula Weight	Mass Used	Moles	Equivalents	Vendor and Lot#
Pd on BaSO ₄		11.8g			Aldrich 08825JR
Norchloroephedrine HCl	206.17	22.4	0.11	1	Product of step 2
Sodium Acetate trihydrate	136.08	58.8g	0.43	4	Mallincrodt 7364KETT

1
 2 A suspension of the sodium acetate, 5% palladium on Barium sulfate and racemic
 3 norchloroephedrine hydrochloride in 186mL glacial acetic acid and 9.7 mL deionized
 4 water was hydrogenated at 50psi for 72h. The reaction was then filtered through celite
 5 and the celite washed with water. The majority of the acetic acid was removed in vacuo
 6 and the pH adjusted to 10 with 10% sodium hydroxide solution. After extracting three
 7 times with ethyl ether, the combined organics were dried over anhydrous sodium sulfate.
 8 The ether was then removed by fractional distillation at ambient pressure, followed by
 9 fractional distillation at 1 mm Hg to yield 11.0g (74 %) of (-)-amphetamine at 99% purity
 10 by Gas Chromatography.

11
 12 **Step 4 - (R, R')-Amphetaminil Sulfate and (R,S')-Amphetaminil Sulfate**



Compound	Formula Weight	Mass Used	Moles	Equivalents	Vendor and Lot#
Amphetamine	135.21	10.43	0.077	1.0	Product of step 3
Benzaldehyde	106.12	8.13g	0.077	1.0	Aldrich 00912LQ
Sodium cyanide	49.01	3.38g	0.069	0.9	Aldrich 00426KB


The amphetamine was suspended in 11mL water. The solution was adjusted to pH7 with 10% sulfuric acid. A solution of the sodium cyanide in 11mL water was then added. The solution went clear. The benzaldehyde dissolved in 27mL methanol was then added over a 10-minute period causing a slight evolution of heat. After stirring for 1h there was no amphetamine left by GC. The reaction mixture was extracted three times with ethyl ether and the combined organics dried over anhydrous sodium sulfate and then filtered. The sulfate salt was immediately made by adding a solution of sulfuric acid and ethyl ether dropwise. The salt was filtered, washed and dried to yield 2.8 grams of a 1:1 mixture of (R, R')-Amphetaminil Sulfate and (R,S')-Amphetaminil Sulfate.

Example 3

Synthesis procedure for (R,R'), (S,S'), (R,S'), (S,R)-Amphetaminil Sulfate,

CSQ-1680E


Step1 – (1S, 2S), (1R,2R) – norchloroephedrine hydrochloride



Compound	Formula Weight	Mass Used	Moles	Equivalents	Vendor and Lot#
Phosphorus pentachloride	208.24	73.1g	0.35	1.3	Aldrich 06011BS
(1S,2R),(1R,2S)Norephedrine hydrochloride	187.67	50.0	0.27	1.0	Aldrich 13713RS

A 1L round bottomed flask was charged with the phosphorus pentachloride and 500 mL anhydrous chloroform. To this stirring mixture under nitrogen was added portion-wise the Norephedrine hydrochloride. The reaction was stirred for 15h after which the precipitate that formed was filtered and washed with chloroform, then dried under high vacuum to yield 47.4g (86%) of a white solid. This material was taken on without further purification.

Step 2 – (+/-)-Amphetamine




Compound	Formula Weight	Mass Used	Moles	Equivalents	Vendor and Lot#
Pd on BaSO4		10.5g			Aldrich 08825JR
Norchlorephedrine	206.17	20.0	0.1	1	Product of prior step
Sodium Acetate trihydrate	136.08	87g	0.64		Mallincrodt 7364KETT

A suspension of the sodium acetate, 5% palladium on Barium sulfate and racemic norchloropidine hydrochloride in 166mL glacial acetic acid was hydrogenated at 50psi for 24h. The reaction was filtered through celite and the celite washed with water. The

1 acetic acid was removed in vacuo and the pH adjusted to 10 with 10% sodium hydroxide
 2 solution. The aqueous solution was extracted three times with ethyl ether and the
 3 combined organics dried over anhydrous sodium sulfate. The ether was then removed by
 4 fractional distillation at ambient pressure, followed by amphetamine distillation at 1 mm
 5 Hg to yield 10.0g (76 %) at 99% purity by Gas Chromatography.

6
 7 **Step 3 - (S, S')-Amphetaminil Sulfate, (S, R')-Amphetaminil Sulfate, (R, R')-**
 8 **Amphetaminil Sulfate, (R, S')-Amphetaminil Sulfate**



16

Compound	Formula Weight	Mass Used	Moles	Equivalents	Vendor and Lot#
Amphetamine	135.21	10.0	0.074	1.0	Product of prior step
Benzaldehyde	106.12	7.73g	0.073	1.0	Aldrich 00912LQ
Sodium cyanide	49.0	2.7g	0.055	0.75	Aldrich 00426KB

1 The amphetamine was suspended in 11 mL water. The solution was adjusted to pH 7
2 with 10% sulfuric acid. A solution of the sodium cyanide in 11mL water was then added.
3 The solution went clear. The benzaldehyde dissolved in 27mL methanol was then added
4 over a 10-minute period causing a slight evolution of heat. After stirring for 1h there was
5 no amphetamine left by GC. The reaction mixture was extracted three times with ethyl
6 ether and the combined organics dried over anhydrous sodium sulfate. Removal of
7 solvent yielded an oil that was precipitated as a solid by the addition of ethanol followed
8 by water. The solid was then recrystallized twice from ethanol/water to yield white
9 crystals.

11 EXAMPLE 4

12 **Effect of (R, R'),(R,S')-Amphetaminil Sulfate (CSQ-1680A) and (R,R'), (S,S'),**
13 **(R,S'), (S,R)-Amphetaminil Sulfate (CSQ-1680E) on locomotor activity and the**
14 **induction of stereotyped behaviour in normal rats: comparison with amphetamine**
15 **and fusaric acid**

17 Male Wistar rats (n=4 per group) were randomly allocated to each drug treatment group.
18 Drugs were administered such that, with the exception of fusaric acid, each rat in each
19 group received all doses of the drug or vehicle in a semi random manner according to the
20 modified Latin Square in Table 1. Compounds were administered at the doses: 0.1, 1 and
21 10mg/kg s.c. in 100% DMSO (vehicle). Amphetamine was administered at 0.1, 1 and 5
22 mg/kg s.c. in saline (vehicle). Fusaric acid was administered at 20, 40 and 80 mg/kg s.c.

1 in saline (vehicle). Rats received each dose of fusaric acid (20, 40 and 80 mg/kg), doses
2 given in order, starting with vehicle. A one-week interval was provided between doses.

3

4 **Table 1** depicts a modified Latin Square for amphetamine and the amphetaminil
5 compositions used in the in-vivo studies. Rats received the following treatments: 1-4,
6 Amphetamine; 9-12, (R, R'),(R, S')-amphetaminil; and 13-16, (R, S'),(R, R'),(S, R'),(S,
7 S')-amphetaminil.

8

Table I

Rat	Week			
	1	2	3	4
1/9/13	A	C	D	B
2/10/14	D	B	A	C
3/11/15	C	A	D	B
4/12/16	B	C	D	A

9

10

Key to Table 1

Treatments	Amphetamine	Amphetaminil composition
A	5mg/kg	0.1mg/kg
B	1mg/kg	1mg/kg
C	0.1mg/kg	10mg/kg
D	control	Control

11

12 At the start of the experiment, rats were placed in standard perspex behaviour boxes with
13 a visible grid on the floor to allow determination of locomotor activity. The animals were
14 allowed to acclimatise to their environment for 1 hour prior to drug/saline administration.
15 Following drug administration animals were returned to the behaviour cages and
16 locomotor activity was assessed for a further 5 hours or until baseline (zero activity for
17 30 minutes) was achieved, whichever was sooner. Locomotor activity was assessed by

1 videoing the rats throughout the experiment, and counting the number of times a rat
 2 crossed a grid line over a period of 5 minutes every 10 minutes. Throughout the
 3 experiment animals were scored for stereotyped behaviours for 15 seconds every 10
 4 minutes by a trained observer using the scoring methods described in Table 2.

7 **Table 2. Stereotypy Scoring**

Number	Behaviour
0	Asleep
1	Inactive
2	Normal activity/ grooming
3	Sniffing/rearing
4	Continuous sniffing and rearing, moving along fixed path
5	Continuous sniffing and rearing, staying in one location
6	Continuous Stereotypy, licking and gnawing
7	Continuous licking and gnawing

9 **Data Analysis**

10 **Locomotor activity Data** The mean and standard error for locomotor activity during 10
 11 minutes for each rat at each time point was determined. This data was analysed by two-
 12 way ANOVA for matched samples (GraphPad Prism). Cumulative activity during the
 13 300 min was also calculated, and the effect of dose of drug was analyzed by 1way
 14 repeated measures ANOVA followed by Dunnett's test (GraphPad Prism). Data was also
 15 analysed for significant fit to a sigmoidal-shaped log dose-response curve using non-
 16 linear regression analysis (GraphPad Prism).

18 **Stereotypy Score Data**

1 The mean and standard error for stereotypy activity for 15 seconds every 10 minutes for
2 each rat at each time point was determined. This data was analysed by two-way ANOVA
3 for matched samples (GraphPad Prism). Cumulative activity during the 300 min was
4 also calculated, and the effect of dose of drug was analyzed by Kruskal Wallis one-way
5 ANOVA (GraphPad Prism). Data was also analysed for significant fit to a sigmoidal-
6 shaped log dose-response curve using non-linear regression analysis (GraphPad Prism)

7 **Results**

9 **Locomotor Activity** Locomotor activity for amphetamine (0.1 – 5 mg/kg sc); fusaric
10 acid (20 – 80 mg/kg sc); (R, R'),(R, S')-amphetaminil (0.1 – 10 mg/kg sc); and (R, S'),
11 (R, R'),(S, R'),(S, S') -amphetaminil (0.1 – 10 mg/kg sc) are shown in Figures 1-4,
12 respectively. Panel A of each figure shows the locomotor activity recorded over time, for
13 each dose and vehicle; panel B the cumulative locomotor activity for each dose; and
14 panel C a dose response.

15
16 Amphetamine (Figure 1) produced a dose-related increase in locomotor activity although
17 data did not fit a sigmoidal-shaped log dose-response curve (Fig 1A-C). Amphetamine
18 (5mg/kg) significantly increased cumulative locomotor activity during the 300 min
19 duration of the experiment (Fig 1A; significant effect of time ($p < 0.001$), treatment
20 ($p < 0.001$), and interaction ($p < 0.001$), 2-way ANOVA). Onset of activity at 5 mg/kg was
21 rapid, with maximum effect seen 30 min after administration. Data represents mean \pm
22 SEM of 4 rats, each rat receiving each dose in a random manner over 4 weeks. In the

1 cumulative figure, $**p < 0.01$ compared to vehicle (Dunnett's t-test). The data does not fit
2 a sigmoidal-shaped log dose-response relationship ($R = 0.788$).
3
4 Fusaric acid (Figure 2) did not increase locomotor activity, however, a small, but
5 significant inhibition of normal activity was observed after administration of 40 mg/kg,
6 but not 80 mg/kg (Fig. 2A-B; significant effect of time ($p < 0.001$), treatment ($p < 0.001$),
7 and interaction ($p < 0.001$), two-way ANOVA). In the cumulative locomotor counts
8 during the 300 minutes post-injection in normal rats, $* p < 0.05$ compared to vehicle
9 (Dunnett's t-test). These data did not fit a sigmoidal-shaped log dose-response
10 relationship (Fig. 2C).
11
12 (R, R'),(R, S')-Amphetaminil (Figure 3) increased locomotor activity only at the highest
13 dose of 10mg/kg (Fig. 3A-B; significant effect of treatment ($p < 0.001$), two-way
14 ANOVA). In the cumulative graph, $* p < 0.05$ compared to vehicle (Dunnett's t-test).
15 These data did not fit a sigmoidal-shaped log dose-response relationship (Fig. 3C).
16
17 Racemic amphetaminil [(R, S'), (R, R'),(S, R'),(S, S')-amphetaminil] (Figure 4)
18 increased locomotor activity only at the highest dose of 10mg/kg (Fig 4A-C). In the
19 cumulative graph, $* p < 0.05$ compared to vehicle (Dunnett's t-test). These data did not fit
20 a sigmoidal-shaped log dose-response relationship ($R = 0.6836$) (Fig 4C).
21
22 **Stereotypy Analyses.**

1 Stereotypy scores for amphetamine (0.1 – 5 mg/kg sc), fusaric acid (20 – 80 mg/kg sc),
 2 (R, R'),(R, S')-amphetaminil (0.1 – 10 mg/kg sc), and (R, S'), (R, R'),(S, R'),(S, S')-
 3 amphetaminil) (0.1 – 10 mg/kg sc) are shown in Figures 5-8. In each figure, panel A
 4 shows the stereotypy scores over time for each dose, panel B the total stereotypy score
 5 for each dose, and panel C the dose-response curve.

6
 7 Amphetamine (Figure 5) produced a log dose-related increase stereotypy (Fig 5A-B;
 8 Significant effect of time ($p < 0.001$), treatment ($p < 0.001$), and interaction ($p < 0.001$), two-
 9 way ANOVA(matching)). Amphetamine (5mg/kg) tended to increase overall stereotypy
 10 during the 300 min duration of the experiment; data fitted a sigmoidal-shaped log dose-
 11 response curve $p < 0.001$, $R = 0.9742$.

12
 13 Fusaric acid (Figure 6) did not increase stereotypy (Fig. 6A-B). However, the animals
 14 tended to sleep more following fusaric acid, although this was not statistically significant
 15 ($p > 0.04$, Kruskal-Wallis).

16
 17 (R, R'),(R, S')-Amphetaminil (Figure 7) tended to increase stereotypy at 10mg/kg (Fig.
 18 7A-C) although differences did not reach statistical significance ($p > 0.05$, Kruskal-
 19 Wallis). The data does not fit a sigmoidal-shaped dose-response relationship.

20
 21 Racemic amphetaminil [(R, S'), (R, R'),(S, R'),(S, S')-amphetaminil] (Figure 8)
 22 increased stereotypy in a log dose-related manner (Fig 8A-C). Onset of stereotypy was
 23 rapid, and, following 10mg/kg, stereotypy was sustained for the duration of the

1 experiment, peaking between 100 and 200min (Significant effect of time ($p<0.001$),
2 treatment ($p<0.001$), and interaction ($p<0.001$), two-way ANOVA(matching)). However,
3 differences in overall stereotypy between groups did not reach statistical significance (Fig
4 8C). The data fits a sigmoidal-shaped log dose-response relationship, $p<0.05$, $R =$
5 0.9834.

6
7 It was found that the R form of the compound exhibited a higher ratio at both the time of
8 peak effect and total effect versus that of the racemic amphetaminil, as set forth below.

9

Compound	Locomotor (Peak)	Stereotypy (Peak)	Ratio (Peak)	Locomotor (Total)	Stereotypy (Total)	Ratio (Total)
(R,R'), (R,S')- amphetaminil	62	3.3	18.8	625	57,	11'
Racemic amphetaminil	37	5.0	7.4	560	115	4.9
Amphetamine	125	5	25	850	81	10.5

10
11

12 The R form thus may be less likely to elicit or exacerbate movement disorders in patients,
13 regardless of the indication for which this compound may be administered. As noted
14 above, tics are prevalent in about 12% of ADHD patients, and thus the R form of
15 amphetaminil may be better suited for such treatment than the racemate.

16

17 The present invention is not to be limited in scope by the specific embodiments describe
18 herein. Indeed, various modifications of the invention in addition to those described
19 herein will become apparent to those skilled in the art from the foregoing description and

1 the accompanying figures. Such modifications are intended to fall within the scope of the
2 appended claims.

3

4 Various publications are cited herein, the disclosures of which are incorporated by
5 reference in their entireties.

09534-4160
T0907-23360